p27Kip1: Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer

Experimental Cell Research

Volumn 264, Issue 1, 2001, Pages 148-168

  Philipp Staheli, Jeannette ^a   Payne, Shannon R ^a   Kemp, Christopher J ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; GENE PRODUCT; PROTEIN P27;

CANCER; CARCINOGENESIS; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CORRELATION FUNCTION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE SWITCHING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

MURINAE;

EID: 0035835828     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2000.5143     Document Type: Article

References (238)

1. A cell cycle-regulated inhibitor of cyclin-dependent kinases
2. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
3. Inhibitors of mammalian G1 cyclin-dependent kinases
4. CDK inhibitors: Positive and negative regulators of G1-phase progression
5. Regulation of the cdk inhibitor p27 and its deregulation in cancer
6. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex
7. Fluorescence in situ hybridization mapping of translocations and deletions involving the short arm of human chromosome 12 in malignant hematologic diseases
8. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer
9. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias
10. p27Kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors
11. The murine Cdkn2a gene (p27/Kip1) maps to distal chromosome 6 and is excluded as Pas1
12. Allelotype analysis of childhood acute lymphoblastic leukemia
13. Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: Evidence for two new tumour-suppressor genes
14. Deletion mapping at 12p12-13 in metastatic prostate cancer
15. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies
16. p27 mutation found in breast cancer
17. Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas
18. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma
19. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer
20. Cancer epigenetics comes of age
21. DNA methylation regulates p27kip1 expression in rodent pituitary cell lines
22. The p27/Kip1 locus shows no loss of heterozygosity in human pituitary adenomas
23. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer
24. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
25. Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries
26. A U-rich element in the 5′ untranslated region is necessary for the translation of p27 mRNA
27. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis
28. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma
29. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer
30. Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer
31. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells
32. Proteasome-dependent degradation of p27/kip1 in gliomas
33. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer
34. Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer
35. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma
36. The murine gene p27Kip1 is haplo-insufficient for tumour suppression
37. Cyclin E-CDK2 is a regulator of p27Kip1
38. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27
39. Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome
40. p45/SKP2 promotes p27/Kip1 degradation and induces S phase in puiescent cells
41. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
42. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination
43. Modification of cullin-1 by ubiquitin-like protein Nedd8 enhances the activity of SCF(skp2) toward p27(kip1)
44. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase
45. Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45(SKP2): Evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway
46. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication
47. Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1
48. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway
49. Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts
50. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1
51. Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27
52. RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity
53. Transformation by Rho exchange factor oncogenes is mediated by activation of an integrin-dependent pathway
54. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells
55. p27KIP1 blocks cyclin E-dependent transactivation of cyclin A gene expression
56. Phosphatidylinositol 3-kinase and NF-kappaB/Rel are at the divergence of CD40-mediated proliferation and survival pathways
57. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression
58. Phosphorylation at serine 10, a major phosphorylation site ofp27(Kip1), increases its protein stability
59. Kip1
60. Critical role for p27Kip1 in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3)
61. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma
62. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1
63. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1
64. Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest
65. Formation of p27-CDK complexes during the human mitotic cell cycle
66. New functional activities for the p21 family of CDK inhibitors
67. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4
68. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts
69. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)
70. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity
71. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
72. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27
73. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes
74. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1)
75. Myc and the cell cycle
76. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc
77. Ras enhances Myc protein stability
78. Identification of G1 kinase activity for cdk6, a novel cyclin D partner
79. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway
80. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization
81. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2
82. Degradation of the cyclin-dependent-kinase inhibitor p27(Kip1) is instigated by Jab1
83. Cloning, expression and subcellular localization of the human homolog of p40MO15 catalytic subunit of cdk-activating kinase
84. Cyclin E-mediated elimination of p27 requires its interaction with the nuclear pore-associated protein mN-PAP60
85. Subcellular distribution of proteasomes implicates a major location of protein degradation in the nuclear envelope-ER network in yeast
86. Localization of the 26S proteasome during mitosis and meiosis in fission yeast
87. A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits
88. The COP9 complex is conserved between plants and mammals and is related to the 26S proteasome regulatory complex
89. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and elF3
90. The PCI domain: A common theme in three multiprotein complexes
91. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes
92. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells
93. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2
94. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27
95. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest
96. Transforming growth factor beta-induced activation of cyclin E-cdk2 kinase and down-regulation of p27Kip1 in C3H 10T1/2 mouse fibroblasts
97. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin
98. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle
99. Dependence of cyclin E-CDK2 kinase activity on cell anchorage
100. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis
101. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells
102. The D-type cyclins and their role in tumorigenesis
103. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta
104. TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: Evidence for cooperation between p21Cip1/WAF1 and p27Kip1
105. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation
106. The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells
107. Growth inhibitory effect of interferon-beta is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1 in a human gastric carcinoma cell line
108. Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK)
109. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells
110. Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: A possible role in tumor growth via an autocrine mechanism
111. Regulation of cell growth by recombinant oncostatin M
112. Cyclin-dependent kinase 6 is the principal target of p27/Kip1 regulation of the G1-phase traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells
113. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells
114. Repression of p27kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells
115. Overexpression of cyclin E in the HC11 mouse mammary epithelial cell line is associated with growth inhibition and increased expression of p27(Kip1)
116. Loss of p27Kip1 from cyclin E/cyclin-dependent kinase (CDK) 2 but not from cyclin D1/CDK4 complexes in cells transformed by polyamine biosynthetic enzymes
117. Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFbeta-treated cells
118. A novel function of adenovirus E1A is required to overcome growth arrest by the CDK2 inhibitor p27(Kip1)
119. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein
120. Binding of polyomavirus small T antigen to protein phosphatase 2A is required for elimination of p27 and support of S-phase induction in concert with large T antigen
121. Expression of the v-Src oncoprotein in fibroblasts disrupts normal regulation of the CDK inhibitor p27 and inhibits quiescence
122. Genetic dissection of cell growth arrest functions mediated by the Epstein-Barr virus lytic gene product, Zta
123. Cell cycle and apoptosis: Common pathways to life and death
124. Apoptosis and the cell cycle
125. Activation of cyclin A-dependent protein kinases during apoptosis
126. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells
127. Promotion of apoptosis: A novel activity associated with the cyclin-dependent kinase inhibitor p27
128. Over-expression of p27kip1 induces growth arrest and apoptosis mediated by changes of pRb expression in lung cancer cell lines
129. Genetic determinants ofp53-induced apoptosis and growth arrest
130. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
131. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma
132. The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene
133. Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells
134. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents
135. p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells
136. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1)
137. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: Role of a caspase cascade
138. Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity
139. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
140. Up-regulation of p27Kip1, p21WAF1/Cip1 and p16Ink4a is associated with, but not sufficient for, induction of squamous differentiation
141. The role of p27kip1 in the in vitro differentiation of murine keratinocytes
142. Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation
143. Comparative effects of overexpression of p27Kip1 and p21Cip1/Waf1 on growth and differentiation in human colon carcinoma cells
144. Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor
145. STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: Role for the cyclin- dependent kinase inhibitor p27(Kip1)
146. Retinoic acid combined with GM-CSF induces morphological changes with segmented nuclei in human myeloblastic leukemia ML-1 cells
147. Complex regulation of CDKs and G1 arrest during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells
148. p27Kip1: A key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line
149. Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism
150. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation
151. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase
152. Reprogramming erythroleuekmia cells to terminal differentiation and terminal cell division
153. Stem cell factor inhibits erythroid differentiation by modulating the activity of G1-cyclin-dependent kinase complexes: A role for p27 in erythroid differentiation coupled G1 arrest
154. Involvement of p21(WAF1/Cip1) and p27(Kip1) in intestinal epithelial cell differentiation
155. p27(Kip1) is an inducer of intestinal epithelial cell differentiation
156. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation
157. Oligodendrocyte precursor differentiation is perturbed in the absence of the cyclin-dependent kinase inhibitor p27Kip1
158. A cyclin-dependent kinase inhibitor, Dacapo, is necessary for timely exit from the cell cycle during Drosophila embryogenesis
159. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27-deficient mice
160. Role of cell shape in growth control
161. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells
162. Differential modulation of G1 cyclins and the Cdk inhibitor p27kip1 by platelet-derived growth factor and plasma factors in density-arrested fibroblasts
163. Inactivation of the cyclin D-dependent kinase in the rat fibroblast cell line, 3Y1, induced by contact inhibition
164. Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension
165. Cadherin-catenin complex: Protein interactions and their implications for cadherin function
166. Functional interaction of beta-catenin with the transcription factor LEF-1
167. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos
168. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1
169. Association of the APC tumor suppressor protein with catenins
170. Association of the APC gene product with beta-catenin
171. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas
172. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain
173. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin
174. Increased cell-substratum adhesion, and decreased gelatinase secretion and cell growth, induced by E-cadherin transfection of human colon carcinoma cells
175. A role for the E-cadherin cell-cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis
176. Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion
177. Cadherin-mediated adhesion is required for normal growth regulation of human gingival epithelial cells
178. Induction of polarized cell-cell association and retardation of growth by activation of the E-cadherin-catenin adhesion system in a dispersed carcinoma line
179. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1)
180. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role
181. p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry
182. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells
183. Direct inhibition of the yeast cyclin-dependent kinase Cdc28-Cln by Far1
184. Pheromone-dependent G1 cell cycle arrest requires Far1 phosphorylation, but may not involve inhibition of Cdc28-Cln2 kinase, in vivo
185. Pheromone signalling and polarized morphogenesis in yeast
186. Nuclear export of Far1p in response to pheromones requires the export receptor Msn5p/Ste21p
187. The role of Far1p in linking the heterotrimeric G protein to polarity establishment proteins during yeast mating
188. A Cdc24p-Far1p-Gbe-tagamma protein complex required for yeast orientation during mating
189. Nuclear sequestration of the exchange factor Cdc24 by Far1 regulates cell polarity during yeast mating
190. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
191. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome
192. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
193. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines
194. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein
195. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: Implication for RAS-dependent Philadelphia chromosome positive cell growth
196. Dominant negative MYC blocks transformation by ABL oncogenes
197. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein
198. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells
199. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells
200. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation
201. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
202. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer
203. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency
204. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225
205. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: Evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1
206. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
207. Mice lacking p27 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors
208. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice
209. Effects of an Rb mutation in the mouse
210. Heterozygous Rb-1 delta 20/+ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance
211. Tumor spectrum in ARF-deficient mice
212. Loss of Apc+ in intestinal adenomas from Min mice
213. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice
214. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1
215. Mutation and cancer: Statistical study of retinoblastoma
216. Skin hyperkeratosis and papilloma formation in transgenic mice expressing a ras oncogene from a suprabasal keratin promoter
217. v-ras genes from Harvey and BALB murine sarcoma viruses can act as initiators of two-stage mouse skin carcinogenesis
218. Carcinogen-specific mutation and amplification of Haras during mouse skin carcinogenesis
219. Tumor suppression by p27/Kip1 and p21/Cip1 during chemically induced skin carcinogenesis
220. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice
221. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis
222. p27Kip1-deficient mice exhibit accelerated growth hormone-releasing hormone (GHRH)-induced somatotrope proliferation and adenoma formation
223. Multiple functions of p27(Kip1) and its alterations in tumor cells: A review
224. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers
225. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas
226. Expression of cell-cycle regulators p27 Kip-1 and cyclin E alone and in combination, correlate with survival in young breast cancer patients
227. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas
228. p27 expression and gastric carcinoma
229. Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors
230. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma
231. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival
232. Cell cycle regulators in bladder cancer: A multivariate survival study with emphasis on p27Kip1
233. Loss of p27(KIP1) expression predicts poor prognosis in patients with esophageal squamous cell carcinoma
234. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases
235. Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: Radiotherapeutic effect and prognosis
236. Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer
237. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy
238. Mouse models in tumor suppression